Ohio is currently home to 3220 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Incremental Hemodialysis: The TwoPlus Trial
NCT05828823
Recruiting
This study is to prospectively compare clinical effectiveness between clinically- matched incremental hemodialysis and conventional hemodialysis in patients with incident kidney dysfunction requiring dialysis and residual kidney function. The study will enroll 350 patients on chronic hemodialysis and 140 caregivers of enrolled patients. Patients will be randomized in 1:1 ratio to either incremental start hemodialysis or conventional hemodialysis. Caregivers will be followed along with patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Cleveland Clinic, Case Western Reserve University (CWRU), Cleveland, Ohio
Conditions: End-Stage Kidney Disease
Register for Updates
Normal Donor Blood Draws for Platelet Studies and Biomarker Evaluation (ND-PLT)
NCT05628974
Recruiting
This is a single-center study at the Cleveland Clinic Main Campus designed to study biomarkers in healthy individuals to identify novel mechanisms of platelet activation and how platelets drive vascular inflammation and thrombosis in diseases.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/12/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Healthy
Register for Updates
Vascular Lab Resource (VLR) Biorepository
NCT05628948
Recruiting
This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular diseas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease, Aneurysmal Disease, Venous Disease, Thrombosis, Lymphedema, Lipedema, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Vasculitis, Fibromuscular Dysplasia, Arterial Dissection, May-Thurner Syndrome, Thoracic Outlet Syndrome, Vasospasm
Register for Updates
Robotic Versus Open Ventral Hernia Repair
NCT05472987
Recruiting
This is a randomized trial comparing open retromuscular ventral hernia repair to robotic retromuscular ventral hernia repair.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Ventral Hernia
Register for Updates
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985
Recruiting
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Christ Hospital Cancer Center, Cincinnati, Ohio
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Register for Updates
Study in Parkinson Disease of Exercise
NCT04284436
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
11/12/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson Disease
Register for Updates
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
NCT04098744
Recruiting
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Gender:
FEMALE
Ages:
Between 25 years and 100 years
Trial Updated:
11/12/2024
Locations: Cleveland Clinic Fairview Hospital, Cleveland, Ohio
Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Register for Updates
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT03932786
Recruiting
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
Gender:
ALL
Ages:
All
Trial Updated:
11/12/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma
Register for Updates
Aggressive Driving and Road Rage: A Driving Simulation Experiment.
NCT03430973
Recruiting
Driving a car is the most dangerous behavior most people engage in every day. According to the World Health Organization, about 1.25 million people die each year as a result of road traffic crashes, and they are the leading cause of death among 15 to 29 year olds. According to the National Highway Traffic Safety Administration, 37,461 Americans were killed in motor vehicle crashes in 2016 - about 103 per day. Although there are several causes of traffic crashes (e.g., texting, alcohol consumptio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: The Ohio State University Driving Simulation Laboratory, Columbus, Ohio
Conditions: Aggression
Register for Updates
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
NCT03266653
Recruiting
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Nationwide Children's Hosptial, Columbus, Ohio
Conditions: Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Register for Updates
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
NCT03266640
Recruiting
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Nationwide Children's Hosptial, Columbus, Ohio
Conditions: Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Register for Updates
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
NCT03266627
Recruiting
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Nationwide Children's Hosptial, Columbus, Ohio
Conditions: Adenovirus, Primary Immune Deficiency Disorder
Register for Updates